A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TOEVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 36 MONTHS INFECTED WITHRESPIRATORY SYNCYTIAL VIRUS (RSV)
Primary Objective To evaluate the antiviral activity of EDP-938 Secondary Objectives To assess the safety and tolerability of EDP-938 To evaluate the PK of EDP-938
